Financial reports
Current reports
8-K
Other Events
2 Feb 18
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
1 Feb 18
8-K
Entry into a Material Definitive Agreement
1 Feb 18
8-K
Other Events
24 Jan 18
8-K
Other Events
18 Jan 18
8-K
Other Events
10 Jan 18
8-K
PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares
15 Dec 17
8-K
Bankruptcy or Receivership
13 Dec 17
8-K
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
28 Nov 17
8-K
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
9 Nov 17
Registration and prospectus
25-NSE
Exchange delisting
19 Apr 18
FWP
Free writing prospectus
10 Jul 17
S-1/A
IPO registration (amended)
6 Jul 17
S-1
IPO registration
21 Jun 17
S-8
Registration of securities for employees
27 Mar 17
S-8
Registration of securities for employees
12 Aug 16
D
$420K in options / securities to be acquired, 1 investor
9 Jun 16
424B4
Prospectus supplement with pricing info
23 May 16
424B4
Prospectus supplement with pricing info
18 May 16
S-1/A
IPO registration (amended)
16 May 16
Other
CT ORDER
Confidential treatment order
19 May 16
EFFECT
Notice of effectiveness
17 May 16
CORRESP
Correspondence with SEC
13 May 16
CORRESP
Correspondence with SEC
13 May 16
CORRESP
Correspondence with SEC
4 May 16
CORRESP
Correspondence with SEC
2 May 16
UPLOAD
Letter from SEC
29 Apr 16
CORRESP
Correspondence with SEC
18 Apr 16
UPLOAD
Letter from SEC
1 Apr 16
UPLOAD
Letter from SEC
11 Mar 16